Fibrocell CEO David Pernock on Fibroblasts and LAVIV; Other Projects in the Works

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.

The company makes LAVIV (azficel-T), a groundbreaking new way to rejuvenate skin. LAVIV is the first and only FDA-approved treatment that uses a patient’s own collagen-producing cells (fibroblasts) to improve the look of smile lines. LAVIV is available exclusively through Fibrocell-trained, board-certified dermatologists and plastic surgeons. An ever growing list of practicing dermatologists and surgeons is available at MyLaviv.com. 

In a recent video interview, Fibrocell CEO David Pernock explains more about what a fibroblast is and how the company's process works: 

“The fibroblasts that we have reside directly under the dermis of the skin and what they're responsible for is the production of collagen and other growth factors, which help to support the skin." He explains that when we age, our number of fibroblasts diminishes. As a result, the skin looks thinner and wrinkles appear.

He continues,

"What we do, through a revolutionary process - actually the first and only of its kind in the world - is to take a small sample of skin from a patient, separate the fibroblast cell, [and] reproduce hundreds of millions of fibroblast cells directly from the patient for reintroduction underneath the skin." 

View the full video below.

See Wikipedia.com for more information on fibroblasts. 

Fibrocell is currently working on other applications for LAVIV, including acne scarring, restrictive burn scars, and vocal cord scarring. The company also has several additional projects in the works, including a personalized skin care cream as a complimentary sale to LAVIV as well as a stem cell program with UCLA and Mit. The company has announced an exclusive license with UCLA on Dermal Cell Research, and a research collaboration with MIT. 

For more information on Fibrocell, see the company's August 2012 Investor Presentation below. 

Fibrocell science investor-presentation-august_2012 from UpGraded Strategies

Fibrocell Science Inc. Initiates Private Stock Sale, Partners with Intrexon Corp. - $FCSC

Fibrocell Science Inc. (OTC: FCSC) has initiated a private stock sale in order to raise $45 million. The sale is restricted to institutional investors and high-net-worth individuals. The company has also formed a partnership with Intrexon Corp., a Blacksburg, Virginia-based synthetic biology company, to further develop its laViv cell therapy technology.

The Exton, Pa., company said the private stock sale involves a select group of institutional investors and high-net-worth individuals, including NRM VII Holdings, a Third Security affiliated fund.

Fibrocell’s laViv launched in 2011 to remove wrinkles. It extracts and multiplies a patient’s collagen-producing cells, then re-injects those cells into the patient. To date, laViv is the only FDA-approved cell therapy technology in aesthetic dermatology. Read more here. 

In a video about laViv’s FDA approval, CEO of Fibrocell Science Inc. David Pernock says,

“Our FDA approval meant the world to our company. What we’re able to do with this support … is offer people a very natural way to correct their nasolabial folds - smile line wrinkles - and not use any synthetic products or mass-produced products—ours is 100 percent made for the patient, specifically for you. It’s a big deal for the company and a big deal for the patients.”

See the full video below.

ProActive Capital Resources Group Announces Client Participation at San Francisco Healthcare Conferences

JP Morgan's 30th Annual Healthcare Conference 

5^th Annual OneMedForum San Francisco 2012

Biotech Showcase 2012 in San Francisco

New York, NY, January 9, 2012 – ProActive Capital Resources Group, a strategic corporate communications, investor relations and social media firm today announced that several of its clients will be presenting at three prestigious investor conferences in San Francisco next week. The following companies will be presenting their corporate presentations at JP Morgan's 30th Annual Healthcare Conference, the 5^th Annual OneMedForum San Francisco 2012, and the Biotech Showcase 2012 in San Francisco.

“We are proud to have several of our clients presenting at these quality industry conferences as we continue to grow our healthcare practice at ProActive Capital,” stated Jeff Ramson, CEO of ProActive Capital Resources Group. “These healthcare conferences provide the visibility and help build awareness as our clients continue to execute on their growth initiatives.”

To schedule a one on one meeting with any of the companies please contact us at the number below.

Coronado Biosciences, Inc. (Nasdaq:CNDO), will present at the Biotech Showcase 2012 Conference on Wednesday, January 11, 2012 at 4:30 PM PT.

Ventrus BioSciences, Inc. (Nasdaq:VTUS) will be attending the conferences and is available for one on one meetings.

Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) will be presenting at JP Morgan's 30th Annual Healthcare Conference on Thursday, January 12, 2012 at 10:00 a.m. PT.

WaferGen Biosystems, Inc. (OTCBB:WGBS.OB) - The company is scheduled to present at OneMedForum on Tuesday, January 10, 2012 beginning at 10:00 a.m. PT.

Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP.OB), will be presenting at the Biotech Showcase 2012 on Monday, January 9, 2012 at 10:00 a.m. PT, as well as on Tuesday, January 10, 2012 at 10:15 a.m. PT at the OneMedForum Conference.

AtheroNova, (OTCQB: AHRO.OB) will be attending the conferences and is available for one on one meetings.

Fibrocell Science, Inc. (OTCBB:FCSC.OB), will be presenting at the 5^th Annual OneMedForum on Wednesday, January 11, 2012 at 10:00 a.m. PT.

Cerecor Inc. (a privately held company) will present at the Biotech Showcase 2012 on Monday, January 9th at 10:00 AM PST. 

NeoStem, Inc. (NYSE Amex: NBS) will be presenting at Biotech Showcase 2012 on January 10, 2012 at 10:30 a.m. PT.

CytoSorbents Corporation (OTC.BB: CTSO.OB), will present at the OneMedForum 2012 on Wednesday, January 11, 2012 at 11:15a.m. PT.

For more information about each of the conferences, go to:

www.onemedplace.com/forum/

http://www.ebdgroup.com/bts/index.php

About ProActive Capital Resources Group, LLC

ProActive Capital Resources Group, LLC (“PACRG”) (www.proactivecrg.com) is dedicated to the discovery and creation of value in the small-cap marketplace. PACRG provides turnkey solutions that combine traditional investor relations services with the latest Internet, mobile and social media communications. The Company’s integrated digital media and global distribution platform www.ProActiveNewsroom.com connects innovative, emerging-growth companies to the investment community using a variety of user-friendly and interactive formats.

Investor Relations Contact:

Jeff Ramson

Proactive Capital Resources Group, LLC.

212-792-4294

jramson@proactivecrg.com